Abstract-We investigated the involvement of different domains of fibronectin in mediating platelet adhesion to fibronectin in the extracellular matrix (ECM) of cultured endothelial cells under flow conditions. Polyclonal anti-fibronectin antibodies were absorbed with Sepharose to which no protein, intact fibronectin, or different fibronectin fragments had been coupled to obtain supernatants (Sups) (Sup 0 , Sup   FN , and Sup name of the fragment , respectively) from which a specific part of the antibodies had been removed. Treatment of the ECM before perfusion with Sup 0 resulted in a 36% decrease in platelet coverage, whereas treatment with Sup FN resulted in maximal adhesion. Treatment of the ECM with supernatants from which antibodies directed against the gelatin-or heparin-binding domain had been removed showed the same inhibition as treatment with Sup 0 . Removal of antibodies directed to the 120-kDa cell-binding domain resulted in a level of adhesion equal to the level found when the ECM was treated with Sup FN . Further analysis of this central region showed that only treatment with supernatants from which antibodies directed to the ninth type III repeat (III-9) of fibronectin had been removed resulted in a significantly higher adhesion than treatment with Sup 0 . Studies of adhesion to the fragments themselves showed that only fragments containing III-10 were able to support adhesion. Mutation of the Arg-Gly-Asp (RGD) sequence into Arg-Gly-Glu (RGE) in one of those fragments resulted in a complete loss of adhesive capacity. These data suggest that platelet adhesion to fibronectin in the ECM depends on III-9, whereas III-10 does not seem to be required. For platelet adhesion to isolated fibronectin, an intact RGD sequence seems to be crucial. Key Words: platelet adhesion Ⅲ fibronectin Ⅲ endothelial cell matrix T he extracellular matrix (ECM) protein fibronectin is involved in a variety of biological processes by mediating cell adhesion and migration. 1 As a constituent of the subendothelium of the vessel wall, it is recognized by blood platelets. In this way, fibronectin contributes to the process of hemostasis, which follows after the vessel has been damaged and the integrity of the endothelial cell layer has been lost.
T he extracellular matrix (ECM) protein fibronectin is involved in a variety of biological processes by mediating cell adhesion and migration. 1 As a constituent of the subendothelium of the vessel wall, it is recognized by blood platelets. In this way, fibronectin contributes to the process of hemostasis, which follows after the vessel has been damaged and the integrity of the endothelial cell layer has been lost.
Fibronectin is composed of 3 types of homologous repeats, designated as types I, II, and III. 2 Proteolysis yields proteaseresistant functional domains that interact with heparin, collagen, fibrin, and cells. The cell-binding domain, which occupies the central region in the molecule, consists of type III repeats, each Ϸ90 amino acids in length. 3 The first sequence in fibronectin found to possess celladhesive properties was the arginine-glycine-aspartic acid (RGD) sequence, which is located in the 10th type III repeat (III-10) of the cell-binding domain. 4 On platelets, this sequence in fibronectin is recognized by 2 receptors, glycoprotein (GP) IIb/IIIa 5, 6 and very late antigen 5 (VLA-5), 7 corresponding to GP Ic/IIa on the platelet. 8 -10 Both receptors are members of the superfamily of integrins, a group of cell surface receptors composed of noncovalently associated ␣-and ␤-subunits. 11 However, several studies have suggested that additional sequences are needed for optimal celladhesive activity. Proteolytic fragments of the cell-binding domain Ͼ75 kDa show adhesive activity equal to that of intact fibronectin, whereas an 11.5-kDa fragment and smaller synthetic peptides display a 20-to 100-fold loss of activity relative to intact fibronectin. 4, [12] [13] [14] Information on the nature of these additional sites has become available from different sources. By use of deletion mutants of fibronectin or specific antibodies, VLA-5-dependent cell spreading has been described to depend on sites in III-7 and/or III-8, 15 III-8 and/or III-9, 16 and III-8 and III-9. [17] [18] [19] For GP IIb/IIIa, additional sites have been mapped to III-9 20, 21 and to the amino-terminal part of III-10. 20 In a previous study, we found that platelet adhesion to isolated surface-immobilized fibronectin under flow conditions was partially inhibited by antibodies directed to VLA-5, whereas an antibody directed to GP IIb/IIIa and an RGD-containing peptide inhibited adhesion almost completely. 22 In contrast, platelet adhesion to a matrix of cultured endothelial cells (ECM) at a low shear rate of 300 s Ϫ1 was not inhibited by these antibodies and the peptide, although adhesion partially depended on fibronectin present in the ECM. 22, 23 In this study, we investigated the role of different fibronectin domains in mediating platelet adhesion to fibronectin in an ECM, and we compare this with adhesion to the isolated protein. We show that fibronectin-dependent adhesion to the ECM involves III-9 of the central cell-binding domain, whereas III-10 does not seem to be required. For adhesion to the isolated protein, an intact RGD sequence seems to be crucial.
Methods

Fibronectin Fragments
Proteolytic Fragments of Fibronectin
Purified human fibronectin was prepared from citrated plasma as described previously by affinity chromatography over a gelatinSepharose (Pharmacia) column. 24 Proteolytic fragments of fibronectin were obtained by digestion with cathepsin D as previously described, 25 with some modifications. Briefly, fibronectin in a 50 mmol/L sodium acetate buffer (pH 3.5) containing 50 mmol/L NaCl, 10 mmol/L EDTA, 0.2 mmol/L PMSF, and 0.02% sodium azide was digested for 3 hours at 37°C with cathepsin D (Sigma Chemical Co; 1:300, wt/wt, enzyme/substrate). The reaction was stopped by raising the pH to 7.5 with a 2.5 mol/L Tris/HCl solution, pH 8.5, and the conductance of the digest was reduced to 6 mho by addition of distilled water. Then the digest was applied to a gelatin-Sepharose column, and the flow-through of this column was passed over a heparin-Sepharose (Pharmacia) column. Both columns were equilibrated with buffer A (20 mmol/L Tris [pH 7.5] containing 50 mmol/L NaCl, 10 mmol/L EDTA, 0.2 mmol/L PMSF, and 0.02% azide). After extensive washing, the gelatin-binding domain was eluted from the gelatin-Sepharose with 50 mmol/L Tris containing 6 mol/L urea and 100 mmol/L citric acid (pH 4.7). Fractions were pooled, dialyzed against 50 mmol/L Tris/100 mmol/L NaCl (pH 7.5), and stored at Ϫ20°C. The cell-binding domain and the high-affinity heparin-binding domain were eluted from the heparin-Sepharose with buffer A containing 0.1 and 0.5 mol/L NaCl, respectively. Fractions were pooled and stored at Ϫ20°C.
Fusion Proteins
Fusion proteins with glutathione-S-transferase (GST) were constructed in the expression vector pRP265, a derivative from the PGEX-2T vector, 26 in which the following polylinker has been cloned into the BamHI/EcoRI site of the original vector: GGATC-CCCATGGTACCCGGGTCGACTAGTATGCATAAGCTTGAATTC BamHI Kpnl AccI NsiI HindIII EcoRI (gift from Dr C. Vink and Dr R.H.A. Plasterk, Netherlands Cancer Institute, Amsterdam). All fragments were produced by polymerase chain reaction (PCR). Plasmid pFH100 (EDII-, EDI-, EDIIICS89), originally constructed by Dufour et al 27 and provided to us by Dr D.F. Mosher (University of Wisconsin, Madison), served as a template. Table 1 shows the primers that were used in the reactions. Fragment FN6 RGE, in which the RGD sequence has been changed into RGE, was produced as 2 PCR fragments (fragments A and B) in which the internal primers cover the site of the mutation (which is underlined). PCR products were separated on a 1% agarose gel, and DNA fragments of the right size were extracted from the gel with Qiagen. PCR products of fragments FN4, FN5, FN6, and FN7 were digested with restriction enzymes and ligated in the respective sites in the vector. PCR products of fragments FN, FN2, FN3, and FN6 RGE were directly inserted into the linearized vector by the exonuclease recession technique. 28 Fragments were cloned into the following sites of the vector: FN4 and FN5 into the KpnI/NsiI sites, FN1, FN2, FN3, FN6, and FN6 RGE into the KpnI/HindIII sites, and FN7 into the BamHI/AccI sites. The authenticity of all fragments was confirmed by both restriction analyses and sequencing according to the method of Sanger et al. 29 The mutation in FN3 RGE was confirmed by restriction analysis using BanII. Proteins were expressed in Escherichia coli and purified out of the soluble fraction of the bacterial lysate with glutathioneSepharose 4B according to the instructions of the manufacturer (Pharmacia). GST alone was used as a control in our experiments. The locations of all fragments, including the recombinant 33-kDa and the 40-kDa fragments, which were a generous gift from Dr T. Vogel [BioTechnology General (Israel) Ltd, Rehovot, Israel], 30 are depicted in Figure 1 .
Antibodies
Polyclonal rabbit anti-human plasma fibronectin antibodies [F(abЈ) 2 fragments] were purchased from Cappel Organon Teknika Corp. The F(abЈ) 2 fragments were prepared from the total IgG fraction in the rabbit serum, including IgG inherent in the rabbit. Peroxidaseconjugated polyclonal swine anti-rabbit antibodies were obtained from Dakopatts. Monoclonal antibodies (MAbs) directed to the cell-attachment site or high-affinity heparin-binding domain in fibronectin were purchased from Boehringer Mannheim. Polyclonal antibody anti-G-TM3, 31 which recognizes GST, was a gift from Dr A. de Ronde (Institute of Virology, Faculty of Veterinary Medicine, Utrecht University, Netherlands).
Protein Characterization
SDS-PAGE was performed according to Laemmli, 32 with the Pharmacia Phastgel system. After purification of the fusion proteins on glutathione beads, we determined the proportion of intact protein in the sample with densitometry (Molecular Dynamics) performed on gels stained with Coomassie brilliant blue. For Western blotting, proteins were transferred to a PVDF membrane (Immobilon-P) by electroblotting. After blotting, the membrane was blocked with a 5% solution of Protifar (Nutricia) in Tris-buffered saline (TBS; 10 mmol/L Tris, 0.9% NaCl, pH 7.4) for 30 minutes. Then the blot was incubated for 1 hour with 5 g/mL polyclonal rabbit anti-human fibronectin antibodies in the same solution. After extensive washing with TBS containing 0.5% Tween 20, the blot was incubated with peroxidase-conjugated swine anti-rabbit antibodies, diluted 1000:1 in the blocking solution. After another extensive washing, the blot was stained with a substrate solution consisting of 5 mg of 3,3Ј-diaminobenzidine (Sigma Chemical Co) per 50 mL of 50 mmol/L Tris (pH 7.4) to which was added 5 L of 30% hydrogen peroxide and 0.03% NiCl 2 .
Surfaces
Surface of Intact Fibronectin or Fibronectin Fragment
Glass coverslips (18ϫ18 mm; Menzel) were cleaned in 80% alcohol, rinsed in distilled water, and dried thoroughly. Per coverslip, 100 L of a solution of an indicated concentration of intact fibronectin or fibronectin fragment, dialyzed against 0.1 mol/L ammonium acetate (pH 7.4), was sprayed with a retouching airbrush (Badger model 100, Badger Brush Co) in such a way that each layer of protein had been dried before the next layer was applied. For the fragments, we corrected the calculated concentration for the proportion of intact fragment present in the protein sample as determined by densitometry. After spraying, the glass coverslips were incubated with a 1% human albumin solution for 1 hour to block aspecific adhesion to glass. No adhesion was found on glass coverslips coated with albumin alone.
Extracellular Matrix
Human umbilical vein endothelial cells were isolated and grown to confluence as described. 33 Cells of the second passage were seeded on glass coverslips coated with gelatin. Cells were removed with 0.1 mol/L NH 4 OH for 15 minutes at room temperature, and subsequently the matrices were washed 3 times with PBS (10 mmol/L phosphate buffer [pH 7.4] and 0.15 mol/L NaCl). The isolation procedure of the ECM did not influence the amount of fibronectin in the ECM, 34 and the matrix is free of cell membrane fragments. 35 
Preparation of Antibody Supernatants
Polyclonal rabbit anti-human fibronectin antibodies, which had previously been shown to completely inhibit adhesion to purified fibronectin, 22 were dissolved in PBS and incubated for 2 hours with intact fibronectin, a fibronectin fragment, or as control for the fusion proteins, GST, which had been coupled to CNBr-activated Sepharose 4B according to the instructions of the manufacturer (Pharmacia). The antibodies were also incubated with CNBr-activated Sepharose that had gone through the whole coupling procedure but to which no protein was coupled. Then the sepharoses were spun down, and the supernatants were collected. Each supernatant (Sup) was named after the protein it had been in contact with (Sup 0 for incubation with Sepharose to which no protein was coupled; Sup FN , were approximately the same, indicating that the specific part of the antibody directed to fibronectin constituted only a very small fraction of the total amount of protein. To check whether adsorption on the sepharoses was complete, we performed ELISAs in which we used intact fibronectin, fibronectin fragments, or GST as first layer, the supernatants as second layer, and peroxidase-conjugated swine anti-rabbit antibodies as the third layer. Sup FN did not react with intact fibronectin or any of the fragments. Sup 0 and Sup GST reacted with intact fibronectin and all fragments, indicating that on each fragment, epitopes were recognized by the polyclonal antibody. The extent of interaction of Sup 0 and Sup GST with intact fibronectin and the fragments was the same, and no reaction was observed with GST. Supernatants that had been in contact with fibronectin fragments coupled to Sepharose no longer reacted with the same fragments in the ELISA, whereas the reaction with nonoverlapping fragments had 
Perfusion Studies
Perfusion studies were performed in a parallel-plate perfusion chamber with well-defined rheological characteristics designed to accommodate duplicate glass coverslips. 36 Whole blood obtained by venipuncture from healthy volunteer donors was anticoagulated with 1/10 volume 110 mmol/L trisodium citrate. Whole blood (15 mL) was prewarmed at 37°C for 5 minutes and then recirculated for 5 minutes at a wall shear rate of 300 s Ϫ1 through the perfusion chamber, which contained 2 protein-sprayed coverslips or coverslips with ECM. In the experiments in which we directly studied the effect of fragments FN4 and FN5 on adhesion, we added the fragments to the perfusate 10 minutes before the perfusion. After perfusion, the coverslips were removed and rinsed with 10 mmol/L HEPES buffer containing 150 mmol/L NaCl (pH 7.35). They were then fixed with 0.5% glutaraldehyde/PBS, dehydrated in methanol, and stained with May-Grünwald-Giemsa stain as described previously. 36 Platelet adhesion was evaluated with a light microscope at ϫ1000 magnification, and the coverage was measured with an Image Analyzer (AMS 40-10). Platelet coverage, expressed as the percentage of the surface covered with platelets, is the average of 60 fields per coverslip.
Statistical Analysis
Preincubation of ECM With Supernatants
The extent of inhibition by treatment with Sup 0 compared with treatment with Sup FN varied slightly among experiments (36.7Ϯ5.8%, meanϮSD; nϭ17), depending on the donor and the batch of ECM that were used each day. Therefore, we compared the platelet coverage found with a certain treatment to the values of minimal (treatment with Sup 0 ) and maximal (treatment with Sup FN ) platelet coverage by transforming values of platelet coverage on individual coverslips according to the following equation:
where C ij represents platelet coverage observed on individual coverslips treated with a certain supernatant (Sup 0 , Sup fragment , or Sup FN ; j) on a certain day (i), and C j,10 and C i,100 represent the mean minimal and maximal platelet coverage corresponding to that day. Two-way ANOVA was performed with a sequential approach in which the effect of a treatment was assessed after adjustment for the effect introduced by different donors/different batches of ECM. To correct for multiple comparisons, the significance level ␣ (0.05) was divided by the total number of comparisons made, 37 the so-called Bonferroni correction, which resulted in a nominal significance level ␣ of 0.0014.
Inhibition of Adhesion by FN4 and FN5
The absolute value of maximal coverage (no addition of fragment) varied among experiments depending on the donor and the batch of ECM or fibronectin that were used on each day. Therefore, we compared the platelet coverage found with a certain concentration of fragment FN4 or FN5 to this value by analyzing the ratio between them instead of absolute differences in platelet coverage. For reasons of normality, the ratios were logarithmically transformed. Two-way ANOVA was performed with a sequential approach in which the effect of a treatment was assessed after adjustment for the effect introduced by different donors/different batches of ECM or fibronectin. To correct for multiple comparisons, the significance level ␣ (0.05) was divided by the number of comparisons made (fibronectin surface: concentrations, ␣ϭ0.017; ECM: 4 concentrations, ␣ϭ0.0125). All statistical analyses were performed according to Sokal and Rohif. 37 
Results
Purification of Fibronectin Fragments
Proteolytic Fragments Purified plasma fibronectin was digested for 3 hours with cathepsin D, and the digest was applied to a gelatinSepharose and a heparin-Sepharose column that were coupled in series. , located at the carboxy-terminal end of the molecule, eluted from the heparin-Sepharose column with 0.5 mol/L NaCl. As previously described, under reducing conditions, the heparin-binding domain migrated as 2 separate bands of Ϸ60 and 70 kDa, because the type III connecting segment is present only in the A chain of fibronectin. 25, 38 Both bands reacted on blot with an mAb directed to the high-affinity heparin-binding site of fibronectin (not shown).
Fusion Proteins
Fibronectin fragments FN1 to FN7 were expressed as fusion proteins of GST. All proteins were purified from the soluble fraction of the bacterial lysate. Figure 3A shows SDS-PAGE analysis of the fusion proteins under reduced conditions after affinity purification on glutathione-Sepharose beads. All proteins migrated approximately at their expected molecular weight (MW) based on their amino acid composition. With FN6 and FN6 RGE, and to a lesser extent with FN1 and FN7, 2 or 3 lower bands with an MW of Ϸ26 kDa comigrated, which reacted on blot with a polyclonal antibody directed to GST (not shown). Figure 3B shows that on blot, all fusion proteins reacted with polyclonal anti-fibronectin antibodies. In samples FN1, FN2, FN6 , and FN6 RGE, some lower bands were visible, which were probably degradation products of the fragments. Fragment FN1 also showed a higher band, which may represent a dimer of the protein. We performed densitometry on Coomassie brilliant blue-stained gels to determine the proportion of intact fragment (ie, fragment of expected MW) in each sample. We found a percentage of 98% for FN3, FN4, and FN5; of 90% for FN1, FN2, and FN7; and of 50% for FN6 and FN6 RGE.
Perfusion Studies
Adhesion Studies
First, we investigated the adhesive capacity of the fragments themselves (Figure 4) . Per coverslip, 100 L of the indicated concentration was sprayed. Subsequently, they were perfused for 5 minutes with whole blood at a shear rate of 300 s
Ϫ1
. Figure 4A shows adhesion to intact fibronectin (FN), the 120-kDa cell-binding domain, and the 33-and 40-kDa fragments, whereas Figure 4B shows adhesion to FN4, FN5, FN6, and GST alone as control for the fusion proteins. As previously described, 22 adhesion to intact fibronectin had its optimum at 720 nmol/L (a spraying concentration of 720 nmol/L equals a surface concentration of 5 g/cm 2 ), whereas a higher concentration resulted in a lower platelet coverage because of loss of platelet spreading. A similar pattern was observed for the 120-kDa cell-binding domain, although the absolute amount of coverage was higher than on intact fibronectin. Fragment FN6 started to show adhesion at the same concentration as intact fibronectin and the 120-kDa fragment, but maximal adhesion was reached at a 2.5 times higher concentration of 1.8 mol/L. Furthermore, we did not observe a decline in platelet coverage at a concentration of 3.6 mol/L. For the other fragments as well, we did not observe this decline in adhesion at higher concentrations.
Fragment FN5 started to show adhesion at a concentration of 0.7 mol/L, reaching maximal adhesion at 3.6 mol/L. Fragment FN4 and the 33-kDa fragment needed a minimal concentration of 1.8 mol/L, whereas maximal adhesion was reached at 7.3 mol/L. The 40-kDa fragment was an exception compared with the other proteins, because it showed a coverage of only 8% over the whole range between 0.9 and 7.3 mol/L. All fragments supported both initial adhesion and platelet spreading. On the basis of the concentration that resulted in half-maximal adhesion (EC 50 ), we can place the fragments in the following order of activity: intact fibronectin/120-kDa fragment (0.3 mol/L) Ͼ FN6 (0.55 mol/L) Ͼ FN5 (1.5 mol/L) Ͼ FN4 (2.5 mol/L) Ͼ33-kDa fragment (3.5 mol/L) (we left out the 40-kDa fragment because of its aberrant behavior). The GST protein itself did not support adhesion ( Figure 4B ), nor did the fusion proteins FN1, FN2, FN3, FN7, and FN6 RGE (not shown). The proteolytically derived gelatin-and heparin-binding domains also were unable to support adhesion (not shown).
Inhibition Experiments
Preincubation of ECM With Different Supernatants
To investigate the role of different domains of fibronectin in adhesion to fibronectin in a more complex system, we circulated blood over ECM. We performed our experiments at a shear rate of 300 s
Ϫ1
, where adhesion to the ECM had previously been described to depend on fibronectin in the matrix but not on the RGD site in this molecule. 23 Polyclonal anti-fibronectin antibodies were incubated with Sepharose to which intact fibronectin, no protein, or a fibronectin fragment had been coupled. In this way, we obtained supernatants in which a specific part of the antibodies had been removed. Treatment of the ECM with Sup FN from which all anti-fibronectin antibodies were removed and Sup 0 that still contained all anti-fibronectin antibodies was 
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considered to result in maximal and minimal platelet coverage, respectively. Treatment with Sup 0 showed a dosedependent inhibition of adhesion. At 750 g/mL, the inhibition was 32.2Ϯ1.5%, whereas a concentration of 1 mg/mL resulted in an inhibition of 34.3Ϯ3.5% (meanϮSEM; nϭ3), indicating that 750 g/mL was sufficient to reach maximal inhibition ( Figure 5 ). For the subsequent experiments ( showed partial recovery of adhesion compared with preincubation with Sup 0 . This suggested that domain III-9 of fibronectin contains adhesive sequence(s). In the following experiments, we tested the direct effect of these 2 fragments on adhesion. Both FN4 and FN5 showed a dose-dependent inhibition of adhesion to isolated fibronectin, reaching a maximal inhibition of 54.4% and 85.4%, respectively, at a concentration of 25 mol/L ( Figure 7A) . ANOVA in which we tested the effect of different concentrations per fragment showed significant (PϽ0.016) reduction of adhesion for fragment FN5 at all concentrations and for fragment FN4 at 10 and 25 mol/L. The IC 50 for FN4 and FN5 were 5.7 and 4 mol/L, respectively. Then we investigated the effect of the fragments on adhesion to the ECM ( Figure 7B ). Fragment FN4 showed no decrease in coverage over the whole range of concentrations up to a concentration of 100 mol/L. Fragment FN5 significantly (PϽ0.0125) reduced adhesion at 50 and 100 mol/L. The IC 50 was 13.7 mol/L.
Discussion
In the present work, we investigated the involvement of different fibronectin domains in fibronectin-dependent platelet adhesion to the ECM, a system that had previously been shown to be a suitable model for the subendothelium. 33 To do so, we prepared a series of fragments, including both proteolytically derived and recombinant fragments. Observations with respect to adhesion to the ECM were compared with results that we obtained in experiments in which we used the fragments themselves as adhesive surface.
Platelet adhesion to isolated fibronectin fully depended on the 120-kDa central cell-binding domain of the molecule: (1) the 120-kDa cell-binding domain and the total fibronectin molecule were equally active (both IC 50 of 0.3 mol/L), and (2) fragments covering the gelatin-or heparin-binding domain were not able to support adhesion. Examination of the adhesive capacity of fragments covering this central region showed that for platelet adhesion to the isolated protein, the RGD sequence was absolutely required. Changing this sequence into RGE, as we did with fragment FN6 RGE, resulted in complete loss of adhesion. All other fragments that did not contain this site, namely FN1, FN2, and FN3, were also unable to support adhesion. The fragments that did support adhesion showed slight differences in activity. The fusion protein FN6 was almost as active as the cell-binding domain (IC 50 of 0.55 mol/L), whereas FN5, FN4, and the 33-kDa fragment showed a slightly increasing IC 50 of 1.5, 2.5, and 3.5 mol/L, respectively. The difference in adhesive capacity between intact fibronectin, the 120-kDa cell-binding domain, and FN6 on one hand, and FN5, FN4, and the 33-kDa fragment on the other hand, may reflect differences in conformation or may be caused by the presence of additional adhesive sites in the larger proteins. A specific conformation of the 40-kDa fragment, a fragment larger than fragment FN4, which supported adhesion very well, may account for the relative inability of this fragment to support adhesion. This may be a consequence of inappropriate folding because the start and end points of the 40-kDa fragment do not correspond to repeat boundaries. It may also be a consequence of the attachment of the protein to the glass coverslip. Previous studies showed that the CS1 region of fibronectin lost activity on adsorption to plastic substrate, 39 which was regained by conjugating the peptide to a carrier protein. 40 Similarly, attachment of the 40-kDa fragment, which was not a fusion protein and thus without carrier, 30 may have resulted in a conformation in which adhesive site(s) were shielded.
With respect to the activity of the different fragments, we found both similarities and differences between platelet adhesion to isolated fibronectin, as described above, and fibronectin in the ECM. As with adhesion to the isolated protein, we found that fibronectin-dependent adhesion to the ECM also completely depended on the 120-kDa central cell-binding domain: (1) preincubation of the polyclonal antibody with the gelatin-or heparin-binding domain did not result in a decrease of the inhibitory capacity of the antibody, and (2) preincubation of the antibody with the 120-kDa cell-binding domain resulted in a complete loss of inhibition of adhesion equal to the loss of inhibition found when the antibody was preincubated with intact fibronectin. Further analysis of this central region showed that adhesion to fibronectin in the ECM, in contrast to adhesion to isolated fibronectin, depended on III-9 instead of III-10: a series of supernatants, which had in common that they were all preincubated with a fragment that contained a complete III- ) or contained an incomplete III-9 (Sup 40kDa ) did not lead to increased coverage. We found further that direct addition of a fragment consisting of only III-10 (FN4) did not decrease the adhesion to the ECM, whereas a fragment containing both III-9 and III-10 (FN5) did reduce adhesion. These data suggest that III-9 contains specific adhesive sequences for platelets adhering to the ECM, whereas III-10, in which the RGD sequence is located, apparently does not contribute to adhesion. To check whether the polyclonal anti-fibronectin antibodies contained inhibitory antibodies directed to III-10 at all, we performed control perfusions in which we used fragment FN4 itself as adhesive surface. Adhesion to this fragment was completely inhibited by the polyclonal antibodies (not shown), indicating that indeed, inhibitory antibodies directed to this repeat were present. These antibodies presumably inhibited the interaction between platelets and the RGD site, because we had found, as described above, that platelet adhesion to fragment FN6 fully depended on this site. Unfortunately, no MAbs directed against FN are known that inhibit adhesion to ECM, and therefore, we must rely on the preadsorbed polyclonal antibodies.
In this article, we present evidence that III-9 supports platelet adhesion to the ECM. However, we cannot completely exclude the possibility that other regions also contribute, because we did not reach complete restoration of adhesion with our fusion proteins, as we did with the 120-kDa cell-binding domain, which was derived from purified plasma fibronectin. We cannot explain this partial restoration, especially because we found that the inhibition caused by direct addition of 100 mol/L of fragment FN5 to the perfusate (34.0Ϯ7.0%, meanϮSD; nϭ5) equaled the inhibition that we observed when we preincubated the ECM with Sup 0 (36.7Ϯ5.8%; nϭ17). A reason might be incomplete absorption of the polyclonal antibodies by the different Sepharoses. However, as described under Experimental Procedures, we established with ELISAs that absorption was complete, indicating that this is not a likely explanation and leaving the question of partial restoration yet unanswered.
Different adhesive sequences have been mapped to III-9. Using chimeric proteins consisting of III-10 and a III-9 in which different amino acids were substituted for the corresponding amino acids in III-8, Aota et al 19 (1) As stated above, the sequence is recognized by VLA-5 and GP IIb/IIIa. However, we found that antibodies directed to these receptors did not inhibit adhesion to the ECM. 22 (2) Bowditch et al 21 showed that binding of III-10 to GP IIb/IIIa was inhibited by this sequence, suggesting that Asp 1371 -Thr 1383 and the RGD sequence represent 2 mutually exclusive sites on fibronectin that compete for binding to this receptor. Such a phenomenon has been described for the RGD site and ␥400 to 411 peptide in fibrinogen. 41 Previous studies, however, showed that platelet adhesion to the ECM was not inhibited by RGDcontaining peptides. 23 Thus, this sequence is not likely to support platelet adhesion to the ECM. Another candidate may be the amino-terminal part of III-9; Katayama et al 16 described an antibody (FN30-8), which inhibited cell adhesion to fibronectin and recognized a fragment of 76 amino acids, which contained part of III-8 and the first 14 amino acids of III-9. If this antibody turns out to recognize this stretch of amino acids in III-9, an adhesive sequence for platelet may be located in this region.
At present, we do not know which platelet receptor will recognize III-9. Tanabe et al 42 described a 29-kDa fragment of fibronectin, spanning the high-affinity heparin domain in which the RGD site was not contained, which bound to purified GP IIb/IIIa and to thrombin-stimulated platelets. This latter interaction was not inhibited by an RGD-containing peptide and an anti-GP IIb/IIIa antibody. This example shows us that, although we previously established that an RGD-containing peptide or an antibody directed to GP IIb/IIIa or VLA-5 did not inhibit adhesion to the ECM, 22, 23 this does not necessarily mean that GP IIb/IIIa or VLA-5 is not involved in this process. We can only speculate why the RGD sequence in matrix fibronectin is not available for platelet adhesion. There are conformational differences between matrix fibronectin and soluble fibronectin coated on glass. Soluble fibronectin is a dimeric glycoprotein with no tendency to polymerize. Matrix fibronectin is an insoluble multimeric form with numerous additional interactions with itself and with other matrix components. There are indications that the RDG-containing III-10 module of fibronectin is involved in matrix assembly. 43 Interaction between the III-10 module with the 70-kD amino-terminal fragment appears to be necessary to allow assembly of fibronectin via this 70-kD fragment into the matrix. Because of this interaction, it is possible that the RDG sequence in III-10 is no longer accessible for integrin binding.
In conclusion, our results suggest that repeat III-9 of fibronectin supports platelet adhesion to the ECM independently from II-10 and, as a consequence, from the RGD site here. In this respect, the adhesion to the ECM differed from adhesion to the isolated protein for which, on the basis of the comparison of the adhesive capacity of fragments FN6 and FN6 RGE, we assume the RGD site to be crucial. Further research will be necessary to identify the exact sequence in III-9 that is recognized and the nature of the receptor involved.
